Literature DB >> 742874

Use of cefoxitin, new cephalosporin-like antibiotic, in the treatment of aerobic and anaerobic infections.

S R Nair, C E Cherubin.   

Abstract

Forty-two patients were treated with intravenous cefoxitin, a new cephamycin antibiotic. These patients had postoperative abdominal sepsis (26), intrathoracic infections (6), urinary tract infections (5), gram-negative bacterial meningitis (2), septic arthritis (1), epidural abscess (1) and isolated septicemia (1). The antibacterial spectrum of cefoxitin was found to be one which included all gram-positive organisms except enterococci, most gram-negative organisms except Pseudomonas aeruginosa, and almost all of the important anaerobic organisms. The only five treatment failures included one patient with empyema and one with septic arthritis, both caused by Serratia marcescens, initially only moderately susceptible to cefoxitin, which subsequently developed increased resistance, two patients with contaminated intravenous catheters, and one patient with epidural abscess and cerebritis, who was treated late in the course. There was one serious clinical superinfection with P. aeruginosa. The drug levels noted in the pus and joint fluid were half to two-thirds of the simultaneous serum level. In inflamed meninges, up to 30% of the serum level was noted in the cerebrospinal fluid, and as the process resolved, 10 to 15% was noted. Toxicity of cefoxitin was mild and constituted skin rash in three patients (7%) and phlebitis in eight (19%).

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 742874      PMCID: PMC352571          DOI: 10.1128/AAC.14.6.866

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

Review 1.  Anaerobic infections (second of three parts).

Authors:  S L Gorbach; J G Bartlett
Journal:  N Engl J Med       Date:  1974-05-30       Impact factor: 91.245

2.  Micromethod system for identification of anaerobic bacteria.

Authors:  S E Starr; F S Thompson; V R Dowell; A Balows
Journal:  Appl Microbiol       Date:  1973-05

3.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

4.  Effects of rate of infusion and probenecid on serum levels, renal excretion, and tolerance of intravenous doses of cefoxitin in humans: comparison with cephalothin.

Authors:  C S Goodwin; E B Raftery; A D Goldberg; H Skeggs; A E Till; C M Martin
Journal:  Antimicrob Agents Chemother       Date:  1974-09       Impact factor: 5.191

5.  Cefoxitin, a semisynthetic cephamycin antibiotic: antibacterial spectrum and resistance to hydrolysis by gram-negative beta-lactamases.

Authors:  H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1974-08       Impact factor: 5.191

6.  Management of anaerobic infections.

Authors:  S M Finegold; J G Bartlett; A W Chow; D J Flora; S L Gorbach; E J Harder; F P Tally
Journal:  Ann Intern Med       Date:  1975-09       Impact factor: 25.391

7.  Antimicrobial therapy of experimental intraabdominal sepsis.

Authors:  W M Weinstein; A B Onderdonk; J G Bartlett; T J Louie; S L Gorbach
Journal:  J Infect Dis       Date:  1975-09       Impact factor: 5.226

8.  Treatment of aspiration pneumonia and primary lung abscess. Penicillin G vs clindamycin.

Authors:  J G Bartlett; S L Gorbach
Journal:  JAMA       Date:  1975-12-01       Impact factor: 56.272

9.  Cefoxitin, a semisynthetic cephamycin antibiotic: resistance to beta-lactamase inactivation.

Authors:  H R Onishi; D R Daoust; S B Zimmerman; D Hendlin; E O Stapley
Journal:  Antimicrob Agents Chemother       Date:  1974-01       Impact factor: 5.191

10.  Simplified assay for gentamicin in the presence of other antibiotics.

Authors:  D V Alcid; S J Seligman
Journal:  Antimicrob Agents Chemother       Date:  1973-05       Impact factor: 5.191

View more
  7 in total

Review 1.  Development of resistance during antibiotic therapy.

Authors:  D Milatovic; I Braveny
Journal:  Eur J Clin Microbiol       Date:  1987-06       Impact factor: 3.267

2.  Emergence of resistance to cefamandole: possible role of cefoxitin-inducible beta-lactamases.

Authors:  C C Sanders; W E Sanders
Journal:  Antimicrob Agents Chemother       Date:  1979-06       Impact factor: 5.191

3.  Penetration of cefoxitin into cerebrospinal fluid of infants and children with bacterial meningitis.

Authors:  W E Feldman; S Moffitt; N S Manning
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

4.  Clinical and pharmacokinetic evaluation of parental cefoxitin in infants and children.

Authors:  W E Feldman; S Moffitt; N Sprow
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

5.  Staphylococcus aureus PBP4 is essential for beta-lactam resistance in community-acquired methicillin-resistant strains.

Authors:  Guido Memmi; Sergio R Filipe; Mariana G Pinho; Zhibiao Fu; Ambrose Cheung
Journal:  Antimicrob Agents Chemother       Date:  2008-08-25       Impact factor: 5.191

6.  Inhibition of WTA synthesis blocks the cooperative action of PBPs and sensitizes MRSA to β-lactams.

Authors:  Maya A Farha; Alexander Leung; Edward W Sewell; Michael A D'Elia; Sarah E Allison; Linda Ejim; Pedro M Pereira; Mariana G Pinho; Gerard D Wright; Eric D Brown
Journal:  ACS Chem Biol       Date:  2012-10-19       Impact factor: 5.100

7.  Dalbavancin exposure in vitro selects for dalbavancin-non-susceptible and vancomycin-intermediate strains of methicillin-resistant Staphylococcus aureus.

Authors:  Brian J Werth; Nathaniel K Ashford; Kelsi Penewit; Adam Waalkes; Elizabeth A Holmes; Dylan H Ross; Tianwei Shen; Kelly M Hines; Stephen J Salipante; Libin Xu
Journal:  Clin Microbiol Infect       Date:  2020-08-28       Impact factor: 13.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.